Delong Liu

Sort by:

Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.

Lu-Lu Lu, Yong-Jun Liu, +9 authors Zhong-chao Han
Haematologica
2006

BACKGROUND AND OBJECTIVES Adult bone marrow (BM) is the major source of mesenchymal stem cells (MSC) for cell therapy. However, aspiration of BM involves invasive procedures. We isolated MSC from… (More)

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Yair Herishanu, Patricia Pérez-Galán, +21 authors Adrian Wiestner
Blood
2011

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes, involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes (LN). A role of the tissue… (More)

Nuclear miRNA regulates the mitochondrial genome in the heart.

Samarjit Das, Marcella Ferlito, +8 authors C. L. M. Steenbergen
Circulation research
2012

RATIONALE Mitochondria are semiautonomous cellular organelles with their own genome, which not only supply energy but also participate in cell death pathways. MicroRNAs (miRNAs) are usually 19 to 25… (More)

Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone.

Kevin W Gaido, Janan B Hensley, +5 authors Kim Boekelheide
Toxicological sciences : an official journal of…
2007

The rat has been explored in detail for its in utero susceptibility to male reproductive tract malformation following phthalate exposure. Few other species have been studied in detail, and it is… (More)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Shuhang Wang, Shundong Cang, Delong Liu
Journal of hematology & oncology
2016

The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to… (More)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L. Petrillo, Delong Liu
Journal of hematology & oncology
2010

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of… (More)

MEK and the inhibitors: from bench to bedside

Akintunde R. Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Mahendra Ravella, Delong Liu
Journal of hematology & oncology
2013

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical… (More)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

Muhammad Furqan, Nikhil Mukhi, Byung Lee, Delong Liu
Biomarker Research
2012

JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction of extracellular signals from cytokines and growth factors involved… (More)

Current management and prognostic features for gastrointestinal stromal tumor (GIST)

Gurpreet S Lamba, Ridhi Das Gupta, Byung Lee, Samir Ambrale, Delong Liu
Experimental hematology & oncology
2012

Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last… (More)

Novel CD20 monoclonal antibodies for lymphoma therapy

Shundong Cang, Nikhil Mukhi, Kemeng Wang, Delong Liu
Journal of hematology & oncology
2012

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences

Organism